Genomic Features of Newly Diagnosed Large B-cell Lymphoma with or without Subsequent Disease Progression
Genomic features of LBCL that can be detected by clinical laboratory assays may predict for resistance to first-line immunochemotherapy, as well as support the exploration of genomic features as biomarkers of response to therapies which could be offered to patients who experience disease progression.
Authors
- Jakub Svoboda (ORCID: https://orcid.org/0000-0002-6359-7065)
- Elise A. Chong (ORCID: https://orcid.org/0000-0001-8895-1625)
- Stefan Klaus Barta (ORCID: https://orcid.org/0000-0002-3280-5271)
- Jennifer J.D. Morrissette (ORCID: https://orcid.org/0000-0001-9460-7177)
- Ashley Barlev
- Daniel J. Landsburg (ORCID: https://orcid.org/0000-0002-5077-4181)
- Salvatore F. Priore
- Stephen J. Schuster (ORCID: https://orcid.org/0000-0002-3376-8978)
- Sunita D. Nasta (ORCID: https://orcid.org/0000-0002-8981-2931)
- Adam Bagg (ORCID: https://orcid.org/0000-0002-1669-468X)
Institutions
- California University of Pennsylvania (US)
- University of Pennsylvania (US)
- Philadelphia University (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0337
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Celgene
- Regeneron Pharmaceuticals
- TG Therapeutics
- Atara Biotherapeutics
- Adaptive Biotechnologies
- BeiGene
- Incyte
- Seagen
- MorphoSys
- Genentech
- Pharmacyclics
- Juno Therapeutics
- Legend Biotech
- Daiichi Sankyo Europe